News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
605,494 Results
Type
Article (39839)
Company Profile (155)
Press Release (565500)
Section
Business (177576)
Career Advice (2005)
Deals (30922)
Drug Delivery (117)
Drug Development (74594)
Employer Resources (154)
FDA (13215)
Job Trends (13416)
News (302171)
Policy (28340)
Tag
2024 BioCapital Digital (9)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (5)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (10)
2024 Biotech Beach Digital (6)
2024 Biotech Beach Standard (2)
2024 Genetown Digital (3)
2024 Genetown Standard (5)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (3)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (4)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Genetown Elite (1)
2026 Pharm Country Premier (1)
2026 Pharm Country Standard (1)
Academia (2291)
Accelerated approval (5)
Adcomms (20)
Allergies (70)
Alliances (41315)
ALS (92)
Alzheimer's disease (1355)
Antibody-drug conjugate (ADC) (120)
Approvals (13222)
Artificial intelligence (217)
Autoimmune disease (19)
Automation (10)
Bankruptcy (296)
Best Places to Work (10567)
BIOSECURE Act (20)
Biosimilars (110)
Biotechnology (76)
Bladder cancer (56)
Brain cancer (24)
Breast cancer (224)
Cancer (1838)
Cardiovascular disease (169)
Career advice (1664)
Career pathing (28)
CAR-T (126)
Cell therapy (356)
Cervical cancer (15)
Clinical research (60736)
Collaboration (670)
Compensation (298)
Complete response letters (26)
COVID-19 (2212)
CRISPR (34)
C-suite (220)
Cystic fibrosis (92)
Data (1857)
Decentralized trials (2)
Denatured (43)
Depression (42)
Diabetes (249)
Diagnostics (5291)
Digital health (12)
Diversity (9)
Diversity, equity & inclusion (43)
Drug discovery (109)
Drug pricing (118)
Drug shortages (32)
Duchenne muscular dystrophy (90)
Earnings (73782)
Editorial (36)
Employer branding (21)
Employer resources (136)
Events (102422)
Executive appointments (666)
FDA (14192)
Featured Employer (30)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (3)
Frontotemporal dementia (8)
Funding (593)
Gene editing (87)
Generative AI (22)
Gene therapy (275)
GLP-1 (731)
Government (3877)
Grass and pollen (3)
Guidances (43)
Healthcare (16783)
Huntington's disease (18)
IgA nephropathy (27)
Immunology and inflammation (111)
Indications (24)
Infectious disease (2338)
Inflammatory bowel disease (128)
Inflation Reduction Act (11)
Influenza (45)
Intellectual property (82)
Interviews (319)
IPO (14001)
IRA (51)
Job creations (3256)
Job search strategy (1442)
Kidney cancer (10)
Labor market (27)
Layoffs (408)
Leadership (17)
Legal (6606)
Liver cancer (56)
Lung cancer (267)
Lymphoma (120)
Machine learning (4)
Management (54)
Manufacturing (257)
MASH (67)
Medical device (10446)
Medtech (10450)
Mergers & acquisitions (17372)
Metabolic disorders (671)
Multiple sclerosis (66)
NASH (22)
Neurodegenerative disease (88)
Neuropsychiatric disorders (29)
Neuroscience (1828)
NextGen: Class of 2025 (5773)
Non-profit (4102)
Northern California (2070)
Now hiring (32)
Obesity (365)
Opinion (244)
Ovarian cancer (72)
Pain (87)
Pancreatic cancer (65)
Parkinson's disease (123)
Partnered (15)
Patents (194)
Patient recruitment (90)
Peanut (41)
People (53041)
Pharmaceutical (80)
Pharmacy benefit managers (21)
Phase I (18896)
Phase II (26410)
Phase III (20401)
Pipeline (1032)
Podcasts (122)
Policy (132)
Postmarket research (2402)
Preclinical (7666)
Press Release (51)
Prostate cancer (88)
Psychedelics (34)
Radiopharmaceuticals (234)
Rare diseases (351)
Real estate (4922)
Recruiting (57)
Regulatory (19695)
Reports (33)
Research institute (2027)
Resumes & cover letters (302)
Rett syndrome (4)
RNA editing (2)
RSV (39)
Schizophrenia (73)
Series A (108)
Series B (66)
Service/supplier (9)
Sickle cell disease (53)
Southern California (1873)
Special edition (18)
Spinal muscular atrophy (137)
Sponsored (24)
Startups (3034)
State (2)
Stomach cancer (13)
Supply chain (58)
Tariffs (14)
The Weekly (77)
United States (18842)
Vaccines (548)
Venture capitalists (33)
Webinars (11)
Weight loss (273)
Women's health (35)
Worklife (18)
Date
Today (95)
Last 7 days (613)
Last 30 days (2477)
Last 365 days (30631)
2025 (7628)
2024 (32147)
2023 (36231)
2022 (46834)
2021 (50329)
2020 (48141)
2019 (41605)
2018 (31548)
2017 (28975)
2016 (28493)
2015 (33137)
2014 (26051)
2013 (21602)
2012 (23553)
2011 (24233)
2010 (22242)
Location
Africa (716)
Alabama (43)
Alaska (5)
Arizona (154)
Arkansas (14)
Asia (37050)
Australia (5581)
California (4749)
Canada (1691)
China (434)
Colorado (226)
Connecticut (217)
Delaware (121)
Europe (81368)
Florida (734)
Georgia (179)
Idaho (44)
Illinois (448)
India (22)
Indiana (284)
Iowa (5)
Japan (137)
Kansas (85)
Kentucky (20)
Louisiana (8)
Maine (63)
Maryland (718)
Massachusetts (3767)
Michigan (172)
Minnesota (315)
Mississippi (2)
Missouri (63)
Montana (26)
Nebraska (23)
Nevada (50)
New Hampshire (50)
New Jersey (1529)
New Mexico (29)
New York (1451)
North Carolina (910)
North Dakota (6)
Northern California (2070)
Ohio (160)
Oklahoma (11)
Oregon (30)
Pennsylvania (1072)
Puerto Rico (10)
Rhode Island (23)
South America (1123)
South Carolina (16)
South Dakota (1)
Southern California (1873)
Tennessee (81)
Texas (721)
Utah (135)
Virginia (128)
Washington D.C. (57)
Washington State (444)
West Virginia (3)
Wisconsin (40)
605,494 Results for "am pharma holding bv".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Amring Pharmaceuticals Inc. Announces Name Change to Nordic Pharma, Inc. Under New Nordic Group, B.V. Ownership
Amring Pharmaceuticals Inc. (“Amring”) announces its name change to Nordic Pharma, Inc. on March 4, 2024, following the change in ownership of the company from SEVER Life Sciences, B.V. to Nordic Group, B.V., a subsidiary of SEVER Life Sciences B.V., which occurred on June 1, 2023.
March 4, 2024
·
3 min read
Press Releases
MilliporeSigma Acquires HUB Organoids Holding B.V., Expands Next-Gen Biology Portfolio
January 7, 2025
·
3 min read
Press Releases
MilliporeSigma to Acquire HUB Organoids Holding B.V., Advancing Next Generation Biology Portfolio
December 17, 2024
·
5 min read
Press Releases
Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET
March 27, 2025
·
5 min read
Pharm Country
Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), to Present Data on LACRIFILL® Canalicular Gel, a Novel Therapy for Dry Eye, at the American Society of Cataract and Refractive Surgery Annual Meeting
Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., will be presenting data on LACRIFILL® Canalicular Gel, a novel therapy for dry eye symptoms, during the American Society of Cataract and Refractive Surgery Annual Meeting in Boston, MA on April 5-8, 2024.
April 2, 2024
·
4 min read
Press Releases
BioVersys Announces Important BV100 Patent Granted by Chinese Patent Office
March 31, 2025
·
5 min read
Pharm Country
Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), Announces the Launch of LACRIFILL® Canalicular Gel, a Novel Therapy for Dry Eye.
Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., has launched LACRIFILL Canalicular Gel, a novel therapy for dry eye in the U.S. LACRIFILL Canalicular Gel is a cross-linked hyaluronic acid derivative and is FDA-cleared to temporarily block tear drainage by the occlusion of the canalicular system.
May 29, 2024
·
3 min read
Press Releases
Zealand Pharma conference call on February 20 at 2pm CET (8am ET) to present full year 2024 financial results
February 14, 2025
·
1 min read
AM-Pharma Announces Updated Clinical Development Strategy
AM-Pharma B.V. announced an updated clinical development strategy to evaluate ilofotase alfa in two indications.
September 26, 2023
·
6 min read
Drug Development
AM-Pharma Initiates Phase 2 Trial of Ilofotase Alfa for Cardiac Surgery-Associated Renal Damage
AM-Pharma B.V. announced that the first patients have been treated in a Phase 2 clinical study evaluating the company’s proprietary recombinant alkaline phosphatase, ilofotase alfa, as a preventive treatment for cardiac surgery-associated renal damage.
January 16, 2024
·
5 min read
1 of 60,550
Next
